Steam turbines produced by the Ural Turbine Works for combined-cycle plants

The most interesting and innovative solutions adopted in the projects of steam turbines for combined-cycle plants with capacities from 115 to 900 MW are pointed out. The development of some ideas and components from the first projects to subsequent ones is shown. © 2013 Pleiades Publishing, Ltd

Treatment of cough in children with ARVI

The article tells about the main mechanisms of cough in children and differential diagnosis of cough. The key features of diseases associated with cough symptoms are described; current approaches to the choice of antitussive therapy in children are considered

Conservative treatment of chemical injury to the nasal mucosa

The article tells about the ways to increase effectiveness of conservative treatment of rhinitis medicamentosa. 112 patients with a long-term history of use of decongestants were observed. A combination drug containing dexpanthenol which stimulates regeneration of the damaged ciliated epithelium was used for the treatment of chemical injury to the mucous membranes of the nose. Using modern methods of research, the authors proved that early treatment of rhinitis medicamentosa with nasal spray containing dexpanthenol, prevents the development of persistent vasomotor dysfunction of the nasal mucosa

EXPERIENCE OF ADALIMUMAB TREATMENT IN PATIENT WITH JUVENILE ANKYLOSING SPONDYLITIS AND UVEITIS

A medical case of early onset and severe course of juvenile ankylosing spondylitis and eyes involvement resistant to routine immunosuppressive drugs is represented in this article. The successful treatment with biological agent adalimumab is described. By the 4th week of treatment the acute inflammatory changes in joints have been arrested, the motion capacity completely restored. By the 8th week of treatment the remission of uveitis has been confirmed, the laboratory indicators of active stage of disease (ESR, serum CRP) have been normalized

ОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБА У БОЛЬНОГО ЮВЕНИЛЬНЫМ АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ И УВЕИТОМ

A medical case of early onset and severe course of juvenile ankylosing spondylitis and eyes involvement resistant to routine immunosuppressive drugs is represented in this article. The successful treatment with biological agent adalimumab is described. By the 4th week of treatment the acute inflammatory changes in joints have been arrested, the motion capacity completely restored. By the 8th week of treatment the remission of uveitis has been confirmed, the laboratory indicators of active stage of disease (ESR, serum CRP) have been normalized.  В данной статье представлен случай раннего дебюта и тяжелого течения ювенильного спондилита с поражением глаз, рефрактерного к терапии классическими иммунодепрессантами. Описано успешное применение биологического агента — адалимумаба. Уже к 4-й нед терапии купировались островоспалительные изменения в пораженных суставах, полностью восстановился объем движений в них; к 8-й нед отмечена ремиссия увеита, нормализовались лабораторные показатели активности заболевания — СОЭ, сывороточная концентрация СРБ.

Contemporary Presentation and Management of Valvular Heart Disease The EURObservational Research Programme Valvular Heart Disease II Survey

International audienceBackground: Valvular heart disease (VHD) is an important cause of mortality and morbidity and has been subject to important changes in management. The VHD II survey was designed by the EURObservational Research Programme of the European Society of Cardiology to analyze actual management of VHD and to compare practice with guidelines. Methods: Patients with severe native VHD or previous valvular intervention were enrolled prospectively across 28 countries over a 3-month period in 2017. Indications for intervention were considered concordant if the intervention was performed or scheduled in symptomatic patients, corresponding to Class I recommendations specified in the 2012 European Society of Cardiology and in the 2014 American Heart Association/American College of Cardiology VHD guidelines. Results: A total of 7247 patients (4483 hospitalized, 2764 outpatients) were included in 222 centers. Median age was 71 years (interquartile range, 62-80 years); 1917 patients (26.5%) were >= 80 years; and 3416 were female (47.1%). Severe native VHD was present in 5219 patients (72.0%): aortic stenosis in 2152 (41.2% of native VHD), aortic regurgitation in 279 (5.3%), mitral stenosis in 234 (4.5%), mitral regurgitation in 1114 (21.3%; primary in 746 and secondary in 368), multiple left-sided VHD in 1297 (24.9%), and right-sided VHD in 143 (2.7%). Two thousand twenty-eight patients (28.0%) had undergone previous valvular intervention. Intervention was performed in 37.0% and scheduled in 26.8% of patients with native VHD. The decision for intervention was concordant with Class I recommendations in symptomatic patients with severe single left-sided native VHD in 79.4% (95% CI, 77.1-81.6) for aortic stenosis, 77.6% (95% CI, 69.9-84.0) for aortic regurgitation, 68.5% (95% CI, 60.8-75.4) for mitral stenosis, and 71.0% (95% CI, 66.4-75.3) for primary mitral regurgitation. Valvular interventions were performed in 2150 patients during the survey; of them, 47.8% of patients with single left-sided native VHD were in New York Heart Association class III or IV. Transcatheter procedures were performed in 38.7% of patients with aortic stenosis and 16.7% of those with mitral regurgitation. Conclusions: Despite good concordance between Class I recommendations and practice in patients with aortic VHD, the suboptimal number in mitral VHD and late referral for valvular interventions suggest the need to improve further guideline implementation